Allergy Therapeutics plc (LON:AGY – Get Free Report) shares fell 5.4% during trading on Wednesday . The stock traded as low as GBX 6.17 and last traded at GBX 7. 567,492 shares traded hands during trading, an increase of 110% from the average session volume of 270,451 shares. The stock had previously closed at GBX 7.40.
Allergy Therapeutics Trading Down 5.4%
The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58. The company has a market cap of £443.28 million, a PE ratio of -7.22, a P/E/G ratio of -30.70 and a beta of 0.87. The company has a fifty day simple moving average of GBX 8.27 and a two-hundred day simple moving average of GBX 10.02.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
